CL2015001814A1 - Composición que comprende al menos un macrólido antibiótico útil para tratar enfermedad genética neurodegenerativa o del neurodesarrollo asociada con una mutación sin sentido; método para tratar dicha enfermedad; método para identificar macrólido antibiótico; ácido nucleíco útil para identificar macrólido antibiótico; vector; y célula hospedadora. - Google Patents

Composición que comprende al menos un macrólido antibiótico útil para tratar enfermedad genética neurodegenerativa o del neurodesarrollo asociada con una mutación sin sentido; método para tratar dicha enfermedad; método para identificar macrólido antibiótico; ácido nucleíco útil para identificar macrólido antibiótico; vector; y célula hospedadora.

Info

Publication number
CL2015001814A1
CL2015001814A1 CL2015001814A CL2015001814A CL2015001814A1 CL 2015001814 A1 CL2015001814 A1 CL 2015001814A1 CL 2015001814 A CL2015001814 A CL 2015001814A CL 2015001814 A CL2015001814 A CL 2015001814A CL 2015001814 A1 CL2015001814 A1 CL 2015001814A1
Authority
CL
Chile
Prior art keywords
antibiotic macrolide
useful
macrolide
neurodevelopmental
treat
Prior art date
Application number
CL2015001814A
Other languages
English (en)
Inventor
Rina Rosin-Arbesfeld
Michal Caspi
Dalia Megiddo
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49956287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of CL2015001814A1 publication Critical patent/CL2015001814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
CL2015001814A 2012-12-24 2015-06-23 Composición que comprende al menos un macrólido antibiótico útil para tratar enfermedad genética neurodegenerativa o del neurodesarrollo asociada con una mutación sin sentido; método para tratar dicha enfermedad; método para identificar macrólido antibiótico; ácido nucleíco útil para identificar macrólido antibiótico; vector; y célula hospedadora. CL2015001814A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745651P 2012-12-24 2012-12-24
US201361762900P 2013-02-10 2013-02-10

Publications (1)

Publication Number Publication Date
CL2015001814A1 true CL2015001814A1 (es) 2015-10-23

Family

ID=49956287

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001814A CL2015001814A1 (es) 2012-12-24 2015-06-23 Composición que comprende al menos un macrólido antibiótico útil para tratar enfermedad genética neurodegenerativa o del neurodesarrollo asociada con una mutación sin sentido; método para tratar dicha enfermedad; método para identificar macrólido antibiótico; ácido nucleíco útil para identificar macrólido antibiótico; vector; y célula hospedadora.

Country Status (16)

Country Link
US (1) US10987370B2 (es)
EP (1) EP2934548A2 (es)
JP (1) JP2016503051A (es)
KR (1) KR20150098675A (es)
AU (1) AU2013368805A1 (es)
BR (1) BR112015015075A2 (es)
CA (1) CA2894992A1 (es)
CL (1) CL2015001814A1 (es)
CR (1) CR20150381A (es)
EA (1) EA201500699A1 (es)
IL (1) IL239467A0 (es)
MD (1) MD20150056A2 (es)
MX (1) MX2015008146A (es)
PE (1) PE20151296A1 (es)
SG (1) SG11201504933WA (es)
WO (1) WO2014102778A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102778A2 (en) 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015192198A1 (en) * 2014-06-19 2015-12-23 The Hospital For Sick Children Treatment of peroxisome biogenesis disorder
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
WO2017010382A1 (ja) * 2015-07-14 2017-01-19 国立大学法人大阪大学 筋強直性ジストロフィー治療薬
CA3005434A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
US11213537B2 (en) 2017-09-18 2022-01-04 Friedrich Miescher Institute For Biomedical Research Inhibition of autism spectrum disorder using ribosomal read-through compounds
WO2023235380A1 (en) * 2022-06-01 2023-12-07 Zikani Therapeutics, Inc. Macrolides for treating genetic diseases

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
IT1176332B (it) 1984-06-27 1987-08-18 Erba Farmitalia Procedimento per al preparazione di peptidi
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
WO2000071557A1 (en) 1999-05-24 2000-11-30 Pfizer Products Inc. 13-methyl-erythromycin derivatives
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20030013692A1 (en) 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
CA2490062A1 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US7291461B2 (en) 2002-06-21 2007-11-06 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7786151B2 (en) * 2004-01-09 2010-08-31 Kinopharma, Inc. Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
WO2005118610A2 (en) * 2004-06-01 2005-12-15 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
EP3121176A1 (en) * 2004-06-08 2017-01-25 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20080221150A1 (en) 2005-08-13 2008-09-11 Shacka John J Prevention of Neurodegeneration by Macrolide Antibiotics
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
JP2009539970A (ja) 2006-06-12 2009-11-19 ラモット アット テル−アビブ ユニバーシティー リミテッド 癌の治療方法
JP5349305B2 (ja) * 2006-08-01 2013-11-20 ファミリーズ オブ スパイナル マスキュラー アトロフィー 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
WO2008150509A1 (en) * 2007-05-31 2008-12-11 The Trustees Of The University Of Pennsylvania Methods and compositions for treating spinal muscular atrophy
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009033722A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a octreotide as a therapeutic agent
US8008344B2 (en) * 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
US20100267712A1 (en) * 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
US20090311695A1 (en) 2008-03-12 2009-12-17 Talat Nasim Method
WO2010033658A2 (en) * 2008-09-17 2010-03-25 The Rockefeller University Cathepsin l proteolytically processes histone h3 during mouse embroyonic stem cell differentiation
US20100152204A1 (en) * 2008-12-15 2010-06-17 Jan-Gowth Chang Treatment for spinal muscular atrophy
US8211631B2 (en) * 2008-12-18 2012-07-03 Wisconsin Alumni Research Foundation In vitro model of spinal muscular atrophy
WO2010084201A1 (en) 2009-01-26 2010-07-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Novel derivative of erythromycin for the treatment and diagnosis of prion disease
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
JP2013506697A (ja) * 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
EP2600865B1 (en) 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP3702460A1 (en) * 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2773212A4 (en) * 2011-10-31 2015-07-01 Univ Johns Hopkins METHODS AND COMPOSITIONS USED FOR THE TREATMENT OF AUTISM
EP2797592B1 (en) * 2011-12-30 2019-08-28 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP2809322B9 (en) * 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
SG10201609188WA (en) * 2012-02-10 2016-12-29 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) * 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9914722B2 (en) * 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014044972A1 (fr) * 2012-09-19 2014-03-27 Centre National De La Recherche Scientifique - Cnrs - Traitement des neuronopathies motrices
WO2014102778A2 (en) 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same

Also Published As

Publication number Publication date
IL239467A0 (en) 2015-07-30
US20150328247A1 (en) 2015-11-19
JP2016503051A (ja) 2016-02-01
AU2013368805A1 (en) 2015-08-13
WO2014102778A2 (en) 2014-07-03
SG11201504933WA (en) 2015-07-30
MD20150056A2 (ro) 2015-09-30
CR20150381A (es) 2015-09-09
US10987370B2 (en) 2021-04-27
BR112015015075A2 (pt) 2019-01-15
WO2014102778A3 (en) 2014-08-21
CA2894992A1 (en) 2014-07-03
PE20151296A1 (es) 2015-10-15
MX2015008146A (es) 2016-01-20
KR20150098675A (ko) 2015-08-28
EP2934548A2 (en) 2015-10-28
EA201500699A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
CL2015001814A1 (es) Composición que comprende al menos un macrólido antibiótico útil para tratar enfermedad genética neurodegenerativa o del neurodesarrollo asociada con una mutación sin sentido; método para tratar dicha enfermedad; método para identificar macrólido antibiótico; ácido nucleíco útil para identificar macrólido antibiótico; vector; y célula hospedadora.
IL263595A (en) A method for targeted modification of DNA in plant cells
HK1215454A1 (zh) 確定樣本基因組中是否存在拷貝數變異的方法、系統和計算機可讀介質
BR112015009114A2 (pt) processo para atualizar uma carga de alimentação orgânica, e, sistema de reator hidrotérmico
SG11201705685VA (en) Using size and number aberrations in plasma dna for detecting cancer
BR112014027464A2 (pt) método para aprimorar o perfil dos produtos, processo e sistema para a produção do butanol.
BR112015005588A2 (pt) sistema e método implementado por computador para perfilamento de utilização de recursos de computação.
BR112015011598A2 (pt) aparelho, método, e um ou mais meios de armazenamento não transitórios, legíveis por computador
BR112015011601A2 (pt) aparelho, método, e um ou mais meios de armazenamento, não transitórios, legíveis por computador
BR112013030816A2 (pt) sistema para teste de segurança automatizado, método para teste de segurança automatizado e mídia não transitória lida por computador
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
BR112017011217A2 (pt) impurezas de dna em uma composição compreendendo um vírion parvoviral
GB201414089D0 (en) Parallelization of surprisal data reduction and genome construction from genetic data for transmission, storage, and analysis
BR112013019097A2 (pt) método,sistema de computador e mídia não transitória lida por computador armazenando um programa
EP3008028A4 (en) System, method and computer readable medium for rapid dna identification
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
BR112014029420A2 (pt) sistema e método para otimizar o número de dados de condicionamento em simulação estatística de múltiplos pontos
IN2015KN00073A (es)
BR112014024216A2 (pt) processo, composições, sistema e produto
GB201502256D0 (en) Solid matrix for one step nucleic acid amplification
FR2992124B1 (fr) Procede de traitement de donnees securise
BR112015014009A2 (pt) processo e dispositivo de agrupamento em lotes de objetos flutuantes.
BR112014032072A2 (pt) método para detectar ácido nucleico e kit de detecção de ácido nucleico.
BR112014028753A2 (pt) processo para umedecer com água superfícies umedecidas com óleo.
BR112014010021A2 (pt) método, sistema, e, mídia legível por computador não transitória